N -(coumarin-3-yl)cinnamamide Promotes Immunomodulatory, Neuroprotective, and Lung Function-Preserving Effects during Severe Malaria.
Paulo Gaio LeiteAllysson T C SoaresNatália Fernanda de Melo OliveiraSamuel PortoLucas KramerRayane Aparecida Nonato RabeloRafaela das Dores PereiraLaura Lis de Oliveira SantosCésar Luís Nascimento BarbosaFabrício Marcus Silva OliveiraMauro Martins TexeiraRemo Castro RussoMaria João MatosFabiana Simão MachadoPublished in: Pharmaceuticals (Basel, Switzerland) (2023)
Plasmodium berghei ANKA (PbA) infection in mice resembles several aspects of severe malaria in humans, such as cerebral malaria and acute respiratory distress syndrome. Herein, the effects of N -(coumarin-3-yl)cinnamamide (M220) against severe experimental malaria have been investigated. Treatment with M220 proved to protect cognitive abilities and lung function in PbA-infected mice, observed by an object recognition test and spirometry, respectively. In addition, treated mice demonstrated decreased levels of brain and lung inflammation. The production and accumulation of microglia, and immune cells that produce the inflammatory cytokines TNF and IFN-γ, decreased, while the production of the anti-inflammatory cytokine IL-10 by innate and adaptive immune cells was enhanced. Treatment with M220 promotes immunomodulatory, neuroprotective, and lung function-preserving effects during experimental severe malaria. Therefore, it may be an interesting therapeutic candidate to treat severe malaria effects.
Keyphrases
- lung function
- plasmodium falciparum
- cystic fibrosis
- chronic obstructive pulmonary disease
- air pollution
- acute respiratory distress syndrome
- early onset
- immune response
- cerebral ischemia
- high fat diet induced
- extracorporeal membrane oxygenation
- inflammatory response
- anti inflammatory
- mechanical ventilation
- drug induced
- intensive care unit
- metabolic syndrome
- type diabetes
- multiple sclerosis
- skeletal muscle
- spinal cord injury